Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Completed Phase 2Phase 3 Interventional

A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results

NCT02355080
View directory record Official record
Conditions
Substance-related Disorders
Interventions
On-site bundled rapid HIV/HCV testing, Standard of care (SOC)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Healthy Heroes Study

NCT03533023
View directory record Official record
Conditions
Shift Workers' Health, Time Restricted Eating, Fasting
Interventions
Time Restricted Eating + Standard of Care, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Coronary CT Angiography in Acute Chest Pain is a Cost Effective Risk Stratification Strategy

NCT00825435
View directory record Official record
Conditions
Acute Chest Pain
Interventions
Coronary CT Angiogram
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

EDX110 Randomized Control Trial for Treatment of DFUs

NCT07209358
View directory record Official record
Conditions
Wound Heal, Diabetic Foot Ulcer
Interventions
EDX110
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Ana, California • Vista, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Not applicable Interventional

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

NCT05506215
View directory record Official record
Conditions
Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
Interventions
SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
Device
Lead sponsor
PolyNovo Biomaterials Pty Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Castro Valley, California • Fresno, California • Vista, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 2 Interventional

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

NCT07291297
View directory record Official record
Conditions
Sarcoma Metastatic, Sarcoma, Soft Tissue
Interventions
Metformin Hydrochloride ER
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Long Term Evaluation Against LDL-C Trial

NCT01439880
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Standard of care
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
78
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 13, 2026, 5:13 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 4 Interventional

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

NCT06999590
View directory record Official record
Conditions
Pressure Ulcer, Ulcer, Ulcer, Pressure, Pressure Injury
Interventions
ACApatch™, caregraFT™, Standard of Care
Other
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
342
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed No phase listed Observational

Gut Microbiome in Colorectal Cancer

NCT04054908
View directory record Official record
Conditions
Gastrointestinal Microbiome, Neoplasm, Colorectal
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 13, 2026, 5:13 PM EDT
Not yet recruiting Not applicable Interventional

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

NCT06989424
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Colonoscopy
Interventions
Magnetic Flexible Endoscope (MFE)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Phase 4 Interventional

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

NCT01608776
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
MIST Therapy, SOC - Standard of Care
Device · Other
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

NCT04633252
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms
Interventions
PDS01ADC, Docetaxel, M7824, Prednisone, ADT
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 4 Interventional

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 2 Interventional

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

NCT06150417
View directory record Official record
Conditions
Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Interventions
Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
Drug · Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) - Atrium Health

NCT05746520
View directory record Official record
Conditions
Appendicitis Surgery
Interventions
Antibiotic
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07187479
View directory record Official record
Conditions
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Interventions
Physiologic Insulin Resensitization (PIR)
Other
Lead sponsor
Well Cell Global
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Not applicable Interventional

Cold and Compression Post TKA

NCT07023185
View directory record Official record
Conditions
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions
Cold and Compression, SOC (Standard of care)
Device · Other
Lead sponsor
Ochsner Health System
Other
Eligibility
50 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

NCT04677777
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
Biological
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional Results available

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
View directory record Official record
Conditions
Covid-19
Interventions
CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Chula Vista, California • El Centro, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 13, 2026, 5:13 PM EDT